Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 10, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory notification of share transactions and does not contain financial performance data.
Material Changes
The filing details specific share transfers from the GlaxoSmithKline Employee Trust ("GSK Trust") to participants in the SmithKline Beecham Employee Share Option Plan 1991:
- March 8, 2006: Transfer of 479,591 Ordinary Shares.
- March 9, 2006: Transfer of 654,596 Ordinary Shares.
The Company was advised of these transactions on March 10, 2006.
Management Commentary and Risks
The GSK Trust is identified as a discretionary trust where all current and former employees of GlaxoSmithKline plc and its subsidiaries are potential beneficiaries. The filing notes that three directors—Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop—hold interests in the shares held by the GSK Trust in the same capacity as other employees. No other risks, contingencies, or unusual items are disclosed in this text.
Investor Verification Points
- Verify the total number of shares transferred (1,134,187) against the company's total outstanding share count to assess dilution impact.
- Confirm the specific terms of the SmithKline Beecham Employee Share Option Plan 1991 regarding vesting and exercise conditions.
- Review the full list of directors to understand the scope of interests held via the GSK Trust beyond the three named individuals.